Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?

Simply Wall St.07-10

Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650972425?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-10 04:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650972425","market":"nz","top_or_hot":-1,"title":"Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 04:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"THNR","symbol_name":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob","article_id":"2650972425","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650972425","pubTimestamp":1783629883,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with excess weight.\nThis first-in-human study expands Viking’s obesity pipeline beyond its GLP‑1/GIP program, highlighting a multi-mechanism approach that could broaden its future treatment profile if development progresses successfully.\nWe’ll now examine how adding VK3019 as an early-stage obesity...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","VKTX":"Viking Therapeutics, Inc.","BK4139":"生物科技","BK4599":"减肥药"},"translate_title":"Viking Therapeutics (VKTX) 扩展到双激动剂肥胖药物是否重新制定了其长期管道战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5,"THNR":0.6,"OZEM":0.6},"content_text":"Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with excess weight. This first-in-human study expands Viking’s obesity pipeline beyond its GLP‑1/GIP program, highlighting a multi-mechanism approach that could broaden its future treatment profile if development progresses successfully. We’ll now examine how adding VK3019 as an early-stage obesity candidate could influence Viking Therapeutics’ broader investment narrative and risk profile. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementViking Therapeutics Investment Narrative RecapTo own Viking Therapeutics today, you need to believe its obesity franchise, led by VK2735, can eventually turn large R&D losses into meaningful revenue despite intense competition and zero current sales. The launch of VK3019 broadens the story beyond a single mechanism, but this Phase 1 trial does not change the near term focus on VANQUISH Phase 3 readouts as the key catalyst or the company’s heavy cash burn as the main risk. The VK3019 first in human trial fits beside Viking’s existing programs, but the most relevant recent update is the progress around VK2735, including VANQUISH-2 enrollment and oral Phase 3 planning. Those late stage obesity programs, supported by ECO data showing double digit weight loss with oral VK2735, remain central to whether current valuation, recent share price strength and optimistic analyst targets can be justified over time. Yet while VK3019 adds a new angle, investors should also be aware of the risk that continued high R&D spending without near term revenue could... Read the full narrative on Viking Therapeutics (it's free!)Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires an earnings increase of about $372.5 million from -$359.6 million today.Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 132% upside to its current price.Exploring Other PerspectivesVKTX 1-Year Stock Price Chart Compared with consensus, the most optimistic analysts were modeling about US$497.5 million of revenue and US$62.2 million of earnings by 2029, so VK3019’s launch may either reinforce that bullish view or prompt you to reconsider how concentrated those expectations still are in VK2735’s success.Explore 12 other fair value estimates on Viking Therapeutics - why the stock might be worth over 2x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.Ready For A Different Approach?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Outshine the giants: these 16 early-stage AI stocks could fund your retirement.Find 44 companies with promising cash flow potential yet trading below their fair value.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650972425","isCrawlerRequest":true}